EKG Criteria for Fibrinolysis: What’s Up with the J Point?

Joseph Brownfield, MD
Mel Herbert, MD
Department of Emergency Medicine, Keck/USC School of Medicine, Los Angeles, CA

Submission history: Submitted May 21, 2007; Accepted November 1, 2007
Reprints available through open access at www.westjem.org

INTRODUCTION

Reading EKGs is an integral skill in Emergency Medicine, especially given the fact that determining the presence and amount of ST segment elevation (STE) is one of the key factors to initiating fibrinolytic eligibility. STE is generally measured in reference to the J point (the end of the QRS segment and the beginning of the ST segment). However, it may not be clear in clinical practice where the J point starts, where one measures ST segment elevation in relation to the J point and finally what the exact degree of elevation of the ST segment makes one a candidate for thrombolysis. Further complicating the issue are numerous other causes of J point and ST segment elevation that are not myocardial-infarction related. This short review will focus on identifying the J point in order to determine an accurate measurement of ST segment elevation and its relationship to fibrinolytic eligibility.

The J Point: Where is it?

One standard text defines J point elevation as: “the point where the QRS ends and the ST segment begins.” Where exactly that “point” resides is rarely stated. One of the more specific descriptors states that the J point is the “first point of the inflection on the upstroke of the S wave.” This description gives one at least some hope of finding a specific point from which to measure. However, we know of no study that has specifically determined the interrater reliability of J point measurements. Studies of the interrater reliability of degree of STE have been performed and generally show considerable disagreement. Since this “point” may be subtle and depend on a variety of factors (the investigator’s vision for example), it may be surmised that the interrater reliability of J point measurement may be less than perfect (Figure 1).

STE and the J point

In theory the ST segment is normally neither elevated nor depressed. STE should be measured from the upper edge of the P-R segment (not the T-P segment) to the upper edge of the ST segment at the J point. In most patients, however, the T-P segment and P-R segment lie on the same plane. Likewise, ST segment depression should be measured from the lower edge of the P-R segment to the lower edge of the ST segment at the J point. If the ST segment is measured with reference to the T-P segment, atrial repolarization with a prominent negative T wave may result in an inaccurate measurement. (See Figure 2).

It is unclear whether STE measured at the J point or 60
milliseconds after the J point is superior when evaluating fibrinolytic or PTCA criteria. A recent retrospective study showed that fewer EKGs met enrollment criteria when based on STE at the J point versus at 60 ms after the J point. Fewer EKGs met an ST score (sum of STE in leads V1-V6) of 6 mm when measured at the J point versus J point plus 60 milliseconds (70% vs. 88%). This controversy is not likely to be resolved any time soon and, in most cases, is probably not important. It is a reminder, however, that criteria that appear to be set in stone, well defined, and closely followed by all experts, are in fact open to interpretation and bias.

**What Degree of STE Equals Fibrinolytic Criteria?**

Marriot’s criteria states that cardiac injury is present when the J point is either elevated by 1 mm or greater in two or more limb leads (or pre-cordial leads V1 to V3), by 2 mm or greater in two or more pre-cordial leads V1 to V3, or is depressed by 1 mm or greater in two or more pre-cordial leads V1 to V3. Recently, there has been a move away from requiring a 2 mm elevation in the anterior pre-cordial leads. The American College of Emergency Physicians (ACEP) Clinical Policies Committee’s 2000 revision states that fibrinolytic criteria includes “ST-segment elevations greater than 0.1 mV in two or more contiguous leads that are not characteristic of early repolarization or pericarditis, nor of a repolarization abnormality from LVH or BBB in patients with clinical presentation suggestive of AMI.”

**Table 1. ECG Entrance Criteria in Select Mega-Trials**

<table>
<thead>
<tr>
<th>Study</th>
<th>Publication Year</th>
<th>Duration of Symptoms Required</th>
<th>Maximum Time to Onset Prior to Presentation</th>
<th>EKG Change Requirements</th>
<th>Other Requirements/Modifiers</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISIS - 1 (13)</td>
<td>1986</td>
<td>----</td>
<td>12 hr</td>
<td>None</td>
<td>MI suspected by MD</td>
</tr>
<tr>
<td>ISIS - 1 (14)</td>
<td>1988</td>
<td>----</td>
<td>24 hr</td>
<td>None</td>
<td>MI suspected by MD</td>
</tr>
</tbody>
</table>
| GISSI - 2 (15) | 1990             | ----                          | 6 hr                                        | 1) STE > 1mm in any limb lead  
2) STE > 2mm in any precordial lead                                                       |                                                                     |
| ISIS - 3 (16)  | 1992             | ----                          | ----                                        | None                                                                                   | MD thought there was a “clear” indication for Fibrinolytics         |
| GUSTO (17)     | 1993             | 20 min                        | 6 hr                                        | 1) STE > 0.1mV in 2 or more limb leads  
2) STE > 0.2mV in 2 or more contiguous precordial leads |                                                                     |
| GUSTO III (18) | 1997             | 30 min                        | 6 hr                                        | 1) STE > 1mm in 2 or more limb leads  
2) STE > 2mm in precordial leads  
3) BBB                                            |                                                                     |
| ASSENT - 2 (19)| 1999             | ----                          | 6 hr                                        | 1) STE > 0.1mV in 2 or more limb leads  
2) STE > 0.2mV in 2 or more contiguous precordial leads  
3) LBBB                              |                                                                     |
| InTIME - II (20)| 2000             | 30 min                        | 6 hr                                        | 1) STE > 0.1mV in any 2 contiguous limb leads  
2) STE > 0.2mV in any 2 contiguous precordial leads  
3) STE > 0.2mV in V4R  
4) STE > 0.2mV in 2 contiguous posterior leads  
5) New or presumed new LBBB |                                                                     |
| ASSENT - 3 (21)| 2001             | ----                          | 6 hr                                        | 1) STE > 0.1mV in 2 or more limb leads  
2) STE > 0.2mV in 2 or more contiguous precordial leads  
3) LBBB                              |                                                                     |
| GUSTO V (22)   | 2001             | 30 min                        | 6 hr                                        | “EKG criteria for STEMI or New LBBB” (with references to GUSTO, GUSTO III & ASSENT – 2) |                                                                     |
It is interesting that many of the largest mega-trials used quite different criteria for fibrinolytic eligibility (Table 1). Indeed some of the mega-trials used no explicit ST segment criteria. The current criteria are derived from retrospective analysis of a combination of mega-trials and therefore have been open to interpretation. The use of 1mm in any 2 contiguous leads has also been deemed acceptable by the American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Regardless, it is best to interpret the ST segment in relation to the clinical history. The higher the pre-test probability of AMI the more comfort one should have in accepting 1mm versus 2mm of ST segment elevation as the criteria for thrombolysis.

SUMMARY
The exact location of the J point, as well as its use for determining STE is open to some debate. Even the exact place to measure ST segment elevation for fibrinolytics is a point of contention, as is the degree of ST segment elevation that warrants consideration of fibrinolytic therapy. Interpreting ST segment elevation must be made in the context of the clinical setting. Like any test, the pre-test probability of the disease (myocardial infarction in this case) is essential in interpreting the results of the test (degree, type and amount of ST segment elevation).

Address for correspondence: Mel Herbert, MD
Keck School of Medicine, LAC+USC Medical Center, Room 1011, 1200 Nth State Street, Los Angeles, CA 90033.
Email: melherbert@cbooth.com

REFERENCES